Online inquiry

IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7404MR)

This product GTTS-WQ7404MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7404MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11795MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ14348MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ14350MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ1623MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ6663MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ6204MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ8785MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ3042MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW